PROVETOP

Human CD27 Ligand/CD70 Protein

Catalog No: CD27-HF003

Species
Human
Expression System
HEK293
Tag
Fc
Activity
Activity verified

Product overview

Recombinant Human CD27 Ligand/CD70 Protein is expressed in HEK293 cells with an hFc (IgG1) at the N-terminus. It contains amino acid residues Gln39-Pro193 (UniProt accession: P32970-1).

Product Details

Molecular Aliases
CD70 molecule; CD70; TNFSF7; CD27 Ligand; CD27-L; CD27LG;-Ki-24 antigen; TNFSF7G;CD27L; -Ki24 antigen
Protein Length
Gln39-Pro193
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 42.7 kDa. Due to glycosylation, the protein migrates to 75-90 kDa under Non reduced (N) condition based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
CD27-HF003 Bis-Tris-PAGE-white result

Human CD27 Ligand on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.

ELISA
CD27-HF003 ELISA result

Immobilized Human CD27, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Human CD27 Ligand, hFc Tag with the EC50 of 14.2ng/ml determined by ELISA.

Background

CD70, also named CD27 ligand (CD27L), is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and has been designated TNFSF7. CD70 is a cytokine that binds to CD27. Plays a role in T-cell activation. Induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells.

References

  1. Buchan S L, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy[J]. Blood, 2017:blood-2017-07-741025.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support